Issue 3
-
Opening Plenary highlights bench-to-bedside aspects of research and clinical treatment
Presenters were (clockwise, from top left): Zhijan Chen, PhD, Mark Dawson, MD, PhD, Melissa Davis, PhD, Karen Vousden, PhD, FAACR, Matthew Vander Heiden, MD, PhD, and Jonathan Weissman, PhD.
-
Clinical Trials Plenary features promising data on targeted therapies for solid tumors
(Clockwise, top left) Lipika Goyal, MD, Vivek Subbiah, MD, Jeffrey Goh, MBBS, and Jermaine Coward, MBBS, PhD, presented during the Annual Meeting’s last Clinical Trials Plenary session.
-
Highlights from the Program Chair: Monday, April 12
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
-
Liquid biopsies hold promise for the future of cancer care
Presenters Caroline Dive, BPharm, PhD, Alberto Bardelli, PhD, and Sarah-Jane Dawson, MBBS, PhD, discussed different uses for this evolving field.
-
Forum considers when the right time is to utilize CAR-T therapies
(From left) Crystal L. Mackall, MD, Hagop M. Kantargian, MD, and Carl H. June, MD, PhD, FAACR, discussed how to decide between monoclonal antibodies, CAR-T therapies, or a combination.
-
Panel explores ongoing controversy of p-values in scientific research
(From left) Steven Goodman, MD, MHS, PhD, Mi-Ok Kim, PhD, and Motomi Mori, PhD, discussed current schools of thought regarding their use or misuse in studies.
-
Opening Ceremony: AACR CEO praises strength of cancer community amid challenging times
“Now, more than ever, it is imperative that our innovative work continues, because patients with cancer around the world are counting on us,” said AACR CEO Margaret Foti, PhD, MD (hc).
-
Leading researchers to discuss their work into understanding the tumor-host ecosystem
Monday’s plenary features presentations from (clockwise, from left) Serena Nik-Zainal, MD, PhD, Ross L. Levine, MD, Jérôme Galon, PhD, and Garry P. Nolan, PhD.